Conference Day 2

Day Two

Thursday, 20th October, 2022

7:30 am
Coffee & Networking

8:25 am Chairman’s Opening Remarks

  • Robert Igarashi Head of Discovery & Pre-Clinical Development, Kiadis, a Sanofi Company

Marrying Innate Immune Biology to Manufacturing Success

8:30 am Maximising Product Stability by Understanding Fundamental Elements of Stability to Advance Cryopreservation Protocols


  • Benchmarking mechanisms of instability to optimise and standardise
    cryopreservation protocols, and enable consistent readings between different sites
  • Harnessing quantified measurements of viability and survival with genome profiling,
    to inform careful comparability studies and yield consistent products
  • Utilising DMSO-free cryopreservation methods and reducing the fill and finish
    timeframe to improve shelf-life, minimise toxicity and enhance potency
  • Reviewing harvest and filling procedures for cryopreservation

9:00 am Enhancing Manufacturing of Lentivirally-Engineered Innate Lymphocytes: There’s an Easy Way

  • Marta Barisa Senior Fellow & Scientific Project Manager, University College London


  • Lentiviral engineering using standard methodology is a major bottleneck for innate cell therapy development
  • UCL has developed a non-VSVg lentiviral engineering strategy optimised for use in innate lymphocytes

9:30 am Utilising Next Generation Gene Editing Techniques to Engineer Novel NK Cells & Overcome Regulatory Hurdles


  • Utilising mRNA gene editing and CRISPR/Cas9 to generate knock-outs and cytokine knock-ins for increased therapeutic action
  • Highlighting in vitro and in vivo data showing improved therapeutic action of CAR-NK therapies
  • Assessing the potential for genome toxicity of CRISPR and mRNA gene editing to maximise product safety

10:00 am Decentralised, Centralised or Regional Manufacture? Topics for Consideration When Determining Your Product Supply Strategy


  • Autologous vs allogenic production: clinical demands and impact on scale of production, and how that influences the clinical or commercial supply strategy
  • Evaluating the pros and cons of decentralised, centralised or regional
    manufacture – are all strategies compatible with both allogeneic and
    autologous production?
  • Addressing logistical challenges specific to allogeneic production and distribution

10:30 am
Morning Refreshments & Networking

Reshaping & Rewiring the Solid Tumour Microenvironment with Novel Approaches

Novel Approaches 101


Gain insights from drug developers and leading academics into the novel cell types emerging as the next generation of therapies. Gain the latest insights into novel biologies and their potential for clinical success, in these 20-minute lightning presentations.

11:30 am Unlocking the Groundbreaking Potential of iNKT Cells for Allogeneic Therapy

11:50 am Arming the Resistance with OPS-gdT – An Allogeneic Immunotherapy for Innate Bystander Recruitment

12:10 pm TCR-NK: A Novel Treatment Paradigm for the Treatment of Solid Cancer

12:30 pm
Ask our Expert Speakers Your Burning Questions

1:00 pm
Lunch & Networking

Achieving Clinical Success in Innate Immune Therapy Trailblazers

2:00 pm Treating Relapsed & Refractory AML with NK to Achieve Complete Response with Haematologic Recovery

  • Robert Igarashi Head of Discovery & Pre-Clinical Development, Kiadis, a Sanofi Company


  • PM21 expanded K-NK cell and off-the-shelf application
  • Describing the multi-dosing strategy to elicit a complete response
  • Outlining current ongoing studies to show efficacy and safety in patients with AML

2:30 pm Bringing Allogeneic NK cells into Clinical Trials for AML


  • Providing an update on oNKord®, an allogeneic NK cell product, in the WiNK AML trial
  • Understanding the safety aspects of the clinical trial for the use of allogeneic NK cells
  • Understanding the role of conditioning chemotherapy for therapeutic efficacy

3:00 pm Panel Discussion: Equipping the Industry to Overcome the Logistical & Technical Challenges of Scaling Up Allogeneic Manufacturing


  • Elucidating the journey from the manufacturing site to patients arm in Europe to allow for smoother transition to clinical investigations
  • Understanding the supply chain system and patient base to build a modular system with clear routes through the supply chain
  • Harnessing intermediate solutions to overcome bottlenecks and improve efficiency of autologous settings before perfecting allogeneic production

4:00 pm Chair’s Closing Remarks & Close of Summit